Johnson & Johnson (0R34) Share Forecast & Price Target

62 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0R34 Analyst Ratings

Moderate Buy

11 Buy

5 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Johnson

& Johnson

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0R34 Stock 12 Month Forecast

Average Price Target

$268.07

▲(14.16% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $268.07 with a high forecast of $298.00 and a low forecast of $250.00. The average price target represents a 14.16% change from the last price of $234.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"150":"$150","299":"$299","187.25":"$187.3","224.5":"$224.5","261.75":"$261.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":298,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$298.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":268.07142857142856,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$268.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$250.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[150,187.25,224.5,261.75,299],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.06,256.5169230769231,259.9738461538462,263.4307692307692,266.8876923076923,270.3446153846154,273.8015384615385,277.2584615384615,280.7153846153846,284.1723076923077,287.6292307692308,291.0861538461538,294.5430769230769,{"y":298,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.06,254.21472527472528,255.36945054945056,256.5241758241758,257.6789010989011,258.8336263736264,259.9883516483516,261.14307692307693,262.2978021978022,263.45252747252744,264.60725274725274,265.761978021978,266.9167032967033,{"y":268.07142857142856,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,253.06,252.82461538461538,252.58923076923077,252.35384615384615,252.11846153846153,251.8830769230769,251.6476923076923,251.4123076923077,251.1769230769231,250.94153846153847,250.70615384615385,250.47076923076924,250.23538461538462,{"y":250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":151.859,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.184,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.774,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.658,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.705,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.217,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.013,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.035,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.059,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.977,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.802,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.06,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$298.00

Average Price Target$268.07

Lowest Price Target$250.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Gerberry

Bank of America Securities

$254→$263

Hold

12.00%

Upside

Reiterated

07/10/26

Bank of America Securities Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Larry Biegelsen

Wells Fargo

$263

Buy

12.00%

Upside

Assigned

07/10/26

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Johnson & Johnson (JNJ)

Terence Flynn

Morgan Stanley

$283→$284

Buy

20.94%

Upside

Reiterated

07/08/26

Johnson & Johnson price target raised to $284 from $283 at Morgan StanleyJohnson & Johnson price target raised to $284 from $283 at Morgan Stanley

Asad Haider

Goldman Sachs

$265→$275

Buy

17.11%

Upside

Assigned

07/08/26

Analysts Conflicted on These Healthcare Names: Sanofi (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ)

Joanne Wuensch

Citi

$285→$298

Buy

26.90%

Upside

Reiterated

07/08/26

Johnson & Johnson (JNJ) Receives a Buy from Citi

Chris Schott

J.P. Morgan

$260

Hold

10.72%

Upside

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Protagonist Therapeutics (NASDAQ: PTGX)

Morten Herholdt

HSBC

$280→$290

Buy

23.49%

Upside

Reiterated

07/06/26

Johnson & Johnson price target raised to $290 from $280 at HSBCJohnson & Johnson price target raised to $290 from $280 at HSBC

Vamil Divan

Guggenheim

$244.88→$270

Buy

14.98%

Upside

Reiterated

06/26/26

Analysts' Top Healthcare Picks: Johnson & Johnson (JNJ), Legend Biotech (LEGN)

Louise Chen

Scotiabank

$265

Buy

12.85%

Upside

Reiterated

06/09/26

Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)

Michael Nedelcovych

TD Cowen

$250

Buy

6.46%

Upside

Reiterated

05/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Risinger

Leerink Partners

$265

Buy

12.85%

Upside

Reiterated

05/15/26

Johnson & Johnson upgraded to Outperform from Market Perform at LeerinkJohnson & Johnson upgraded to Outperform from Market Perform at Leerink

Matt Miksic

Barclays

$255

Hold

8.59%

Upside

Reiterated

05/13/26

Analysts Conflicted on These Healthcare Names: Altimmune (NASDAQ: ALT), Brookdale Senior Living (NYSE: BKD) and Johnson & Johnson (NYSE: JNJ)

Hans Engel

Erste Group

―

Buy

―

Reiterated

05/05/26

Analysts Are Bullish on Top Healthcare Stocks: Johnson & Johnson (JNJ), HealthStream (HSTM)

Rick Wise

Stifel Nicolaus

$220→$250

Hold

6.46%

Upside

Assigned

04/15/26

Johnson & Johnson price target raised to $250 from $220 at StifelJohnson & Johnson price target raised to $250 from $220 at Stifel

Shagun Singh Chadha

RBC Capital

$255→$265

Buy

12.85%

Upside

Reiterated

04/14/26

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Gerberry

Bank of America Securities

$254→$263

Hold

12.00%

Upside

Reiterated

07/10/26

Bank of America Securities Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Larry Biegelsen

Wells Fargo

$263

Buy

12.00%

Upside

Assigned

07/10/26

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Johnson & Johnson (JNJ)

Terence Flynn

Morgan Stanley

$283→$284

Buy

20.94%

Upside

Reiterated

07/08/26

Johnson & Johnson price target raised to $284 from $283 at Morgan StanleyJohnson & Johnson price target raised to $284 from $283 at Morgan Stanley

Asad Haider

Goldman Sachs

$265→$275

Buy

17.11%

Upside

Assigned

07/08/26

Analysts Conflicted on These Healthcare Names: Sanofi (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ)

Joanne Wuensch

Citi

$285→$298

Buy

26.90%

Upside

Reiterated

07/08/26

Johnson & Johnson (JNJ) Receives a Buy from Citi

Chris Schott

J.P. Morgan

$260

Hold

10.72%

Upside

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Protagonist Therapeutics (NASDAQ: PTGX)

Morten Herholdt

HSBC

$280→$290

Buy

23.49%

Upside

Reiterated

07/06/26

Johnson & Johnson price target raised to $290 from $280 at HSBCJohnson & Johnson price target raised to $290 from $280 at HSBC

Vamil Divan

Guggenheim

$244.88→$270

Buy

14.98%

Upside

Reiterated

06/26/26

Analysts' Top Healthcare Picks: Johnson & Johnson (JNJ), Legend Biotech (LEGN)

Louise Chen

Scotiabank

$265

Buy

12.85%

Upside

Reiterated

06/09/26

Scotiabank Sticks to Their Buy Rating for Johnson & Johnson (JNJ)

Michael Nedelcovych

TD Cowen

$250

Buy

6.46%

Upside

Reiterated

05/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Risinger

Leerink Partners

$265

Buy

12.85%

Upside

Reiterated

05/15/26

Johnson & Johnson upgraded to Outperform from Market Perform at LeerinkJohnson & Johnson upgraded to Outperform from Market Perform at Leerink

Matt Miksic

Barclays

$255

Hold

8.59%

Upside

Reiterated

05/13/26

Analysts Conflicted on These Healthcare Names: Altimmune (NASDAQ: ALT), Brookdale Senior Living (NYSE: BKD) and Johnson & Johnson (NYSE: JNJ)

Hans Engel

Erste Group

―

Buy

―

Reiterated

05/05/26

Analysts Are Bullish on Top Healthcare Stocks: Johnson & Johnson (JNJ), HealthStream (HSTM)

Rick Wise

Stifel Nicolaus

$220→$250

Hold

6.46%

Upside

Assigned

04/15/26

Johnson & Johnson price target raised to $250 from $220 at StifelJohnson & Johnson price target raised to $250 from $220 at Stifel

Shagun Singh Chadha

RBC Capital

$255→$265

Buy

12.85%

Upside

Reiterated

04/14/26

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

3 Months

Danielle AntalffyUBS

Success Rate

23/27 ratings generated profit

Average Return

+4.81%

Copying Danielle Antalffy's trades and holding each position for 3 Months would result in 85.19% of your transactions generating a profit, with an average return of +4.81% per trade.

1 Year

Danielle AntalffyUBS

Success Rate

27/27 ratings generated profit

Average Return

+14.39%

Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.39% per trade.

2 Years

Shagun Singh ChadhaRBC Capital

Success Rate

27/27 ratings generated profit

Average Return

+52.89%

Copying Shagun Singh Chadha's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R34 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0R34 has received 18 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 0R34 average Analyst price target in the past 3 months is 268.07.

Each month's total comprises the sum of three months' worth of ratings.

0R34 Financial Forecast

0R34 Earnings Forecast

Next quarter’s earnings estimate for 0R34 is $2.86 with a range of $2.65 to $3.00. The previous quarter’s EPS was $2.70. 0R34 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 0R34 has Performed in-line its overall industry.

0R34 Sales Forecast

Next quarter’s sales forecast for 0R34 is $25.02B with a range of $23.97B to $25.48B. The previous quarter’s sales results were $24.07B. 0R34 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 0R34 has Performed in-line its overall industry.

0R34 Stock Forecast FAQ

What is GB:0R34’s average 12-month price target, according to analysts?

Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 268.07.

What is GB:0R34’s upside potential, based on the analysts’ average price target?

Johnson & Johnson has 14.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Johnson & Johnson a Buy, Sell or Hold?

Johnson & Johnson has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.

What is Johnson & Johnson’s share price target?

The average share price target for Johnson & Johnson is 268.07. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $298.00 ,and the lowest forecast is $250.00. The average share price target represents 14.16% Increase from the current price of $234.83.

What do analysts say about Johnson & Johnson?

Johnson & Johnson’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Johnson & Johnson?

To buy shares of GB:0R34, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Johnson & Johnson (0R34) Share Forecast & Price Target

0R34 Analyst Ratings

0R34 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Johnson & Johnson

0R34 Analyst Recommendation Trends

0R34 Financial Forecast

0R34 Earnings Forecast

0R34 Sales Forecast

0R34 Stock Forecast FAQ

Detailed List of Analyst Forecasts